United Therapeutics Corporation United Therapeutics Corporation United Therapeutics Corporation

TYVASO treprostinil TREPROSTINIL TREPROSTINIL SODIUM CHLORIDE TRISODIUM CITRATE DIHYDRATE SODIUM HYDROXIDE HYDROCHLORIC ACID WATER

Warnings and Precautions (5.4)

05/2022

Tyvaso is a prostacyclin mimetic indicated for the treatment of: Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). (1.1) Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%). (1.2)

Tyvaso is indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities. While there are long-term data on use of treprostinil by other routes of administration, nearly all controlled clinical experience with inhaled treprostinil has been on a background of bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase type 5 inhibitor). The controlled clinical experience was limited to 12 weeks in duration [see Clinical Studies (14)].

Tyvaso is indicated for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%) [see Clinical Studies (14)].

Use only with the Tyvaso Inhalation System. (2.1) Administer undiluted, as supplied. A single breath of Tyvaso delivers approximately 6 mcg of treprostinil. (2.1) Administer in 4 separate treatment sessions each day approximately 4 hours apart, during waking hours. (2.1) Initial dosage: 3 breaths (18 mcg) per treatment session. If 3 breaths are not tolerated, reduce to 1 or 2 breaths. (2.1) Dosage should be increased by an additional 3 breaths per treatment session at approximately 1- to 2-week intervals, if tolerated. (2.1) Titrate to target maintenance doses of 9 to 12 breaths per treatment session, 4 times daily. (2.1)

Tyvaso is intended for oral inhalation using the Tyvaso Inhalation System, which consists of an ultrasonic, pulsed delivery device and its accessories. Tyvaso is dosed in 4 separate, equally spaced treatment sessions per day, during waking hours. Each treatment session will take 2 to 3 minutes. The treatment sessions should be approximately 4 hours apart.

Initial Dosage: Therapy should begin with 3 breaths of Tyvaso (18 mcg of treprostinil) per treatment session 4 times daily. If 3 breaths are not tolerated, reduce to 1 or 2 breaths and subsequently increase to 3 breaths, as tolerated.

Maintenance Dosage: Dosage should be increased by an additional 3 breaths per treatment session, 4 times daily at approximately 1- to 2-week intervals. Studies establishing effectiveness in patients with PAH and PH-ILD have used target doses of 9 to 12 breaths per treatment session, 4 times daily. If adverse effects preclude titration to target dose, Tyvaso should be continued at the highest tolerated dose. If a scheduled treatment session is missed or interrupted, therapy should be resumed as soon as possible at the usual dose.

Tyvaso must be used only with the Tyvaso Inhalation System. Patients should follow the instructions for use for operation of the Tyvaso Inhalation System and for daily cleaning of the device components after the last treatment session of the day. To avoid potential interruptions in drug delivery because of equipment malfunction, patients should have access to a back-up Tyvaso Inhalation System device. Do not mix Tyvaso with other medications in the Tyvaso Inhalation System. Compatibility of Tyvaso with other medications has not been studied. The Tyvaso Inhalation System should be prepared for use each day according to the instructions for use. One ampule of Tyvaso contains a sufficient volume of medication for all 4 treatment sessions in a single day. Prior to the first treatment session, the patient should twist the top off a single Tyvaso ampule and squeeze the entire contents into the medicine cup. Between each of the 4 daily treatment sessions, the device should be capped and stored upright with the remaining medication inside. At the end of each day, the medicine cup and any remaining medication must be discarded. The device must be cleaned each day according to the instructions for use. Avoid skin or eye contact with Tyvaso solution. Do not orally ingest the Tyvaso solution.

Sterile solution for oral inhalation: 2.9 mL ampule containing 1.74 mg of treprostinil (0.6 mg per mL). Sterile solution for oral inhalation: 2.9 mL ampule containing 1.74 mg treprostinil (0.6 mg per mL). (3)

None. None. (4)

Tyvaso may cause symptomatic hypotension. (5.1) Tyvaso inhibits platelet aggregation and increases the risk of bleeding. (5.2) Tyvaso dosage adjustments may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn. (5.3, 7.3) May cause bronchospasm: Patients with a history of hyperreactive airway disease may be more sensitive. (5.4)

Treprostinil is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, treatment with Tyvaso may produce symptomatic hypotension.

Tyvaso inhibits platelet aggregation and increases the risk of bleeding.

Co-administration of a cytochrome P450 (CYP) 2C8 enzyme inhibitor (e.g., gemfibrozil) may increase exposure (both Cmax and AUC) to treprostinil. Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. Increased exposure is likely to increase adverse events associated with treprostinil administration, whereas decreased exposure is likely to reduce clinical effectiveness [see Drug Interactions (7.3) and Clinical Pharmacology (12.3)].

Like other inhaled prostaglandins, Tyvaso may cause acute bronchospasm. Patients with asthma or chronic obstructive pulmonary disease (COPD), or other bronchial hyperreactivity, are at increased risk for bronchospasm. Ensure that such patients are treated optimally for reactive airway disease prior to and during treatment with Tyvaso Inhalation Solution.

The following potential adverse reactions are described in Warnings and Precautions (5): -Decrease in systemic blood pressure [see Warnings and Precautions (5.1)]. -Bleeding [see Warnings and Precautions (5.2)]. Most common adverse reactions (≥4%) are cough, headache, nausea, dizziness, flushing, throat irritation, pharyngolaryngeal pain, diarrhea, and syncope. (6)
To report SUSPECTED ADVERSE REACTIONS, contact United Therapeutics Corp. at 1-866-458-6479 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Pulmonary Arterial Hypertension In a 12-week, placebo-controlled study (TRIUMPH I) of 235 patients with PAH (WHO Group 1 and nearly all NYHA Functional Class III), the most commonly reported adverse reactions on Tyvaso included cough and throat irritation, headache, gastrointestinal effects, muscle, jaw or bone pain, dizziness, flushing, and syncope. Table 1 lists the adverse reactions that occurred at a rate of at least 4% and were more frequent in patients treated with Tyvaso than with placebo.

Table 1: Adverse Events in ≥4% of PAH Patients Receiving Tyvaso and More FrequentMore than 3% greater than placebo than Placebo in TRIUMPH I

Adverse Event	Treatment n (%)
	Tyvaso n=115	Placebo n=120
Cough	62 (54)	35 (29)
Headache	47 (41)	27 (23)
Throat Irritation / Pharyngolaryngeal Pain	29 (25)	17 (14)
Nausea	22 (19)	13 (11)
Flushing	17 (15)	1 (<1)
Syncope	7 (6)	1 (<1)

The safety of Tyvaso was also studied in a long-term, open-label extension study in which 206 patients were dosed for a mean duration of 2.3 years, with a maximum exposure of 5.4 years. Eighty-nine percent (89%) of patients achieved the target dose of 9 breaths, 4 times daily. Forty-two percent (42%) achieved a dose of 12 breaths, 4 times daily. The adverse events during this chronic dosing study were qualitatively similar to those observed in the 12-week placebo-controlled trial. In a prospective, observational study comparing patients taking Tyvaso (958 patient-years of exposure) and a control group (treatment with other approved therapies for PAH; 1094 patient-years), Tyvaso was associated with a higher rate of cough (16.2 vs. 10.9 per 100 patient-years), throat irritation (4.5 vs. 1.2 per 100 pt-years), nasal discomfort (2.6 vs. 1.3 per 100 pt-years), and hemoptysis (2.5 vs. 1.3 per 100 pt-years) compared to the control group.

Pulmonary Hypertension Associated with ILD In a 16-week, placebo-controlled study (INCREASE) of 326 patients with PH-ILD (WHO Group 3), adverse reactions were similar to the experience in studies of PAH.

The adverse reaction of angioedema has been identified during the post-approval use of Tyvaso. Because this reaction is reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.

In a human pharmacokinetic study conducted with bosentan (250 mg/day) and an oral formulation of treprostinil (treprostinil diolamine), no pharmacokinetic interactions between treprostinil and bosentan were observed.

In a human pharmacokinetic study conducted with sildenafil (60 mg/day) and an oral formulation of treprostinil (treprostinil diolamine), no pharmacokinetic interactions between treprostinil and sildenafil were observed.

In vitro studies of human hepatic microsomes showed that treprostinil does not inhibit cytochrome P450 (CYP) isoenzymes CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A. Additionally, treprostinil does not induce cytochrome P450 isoenzymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A. Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor, gemfibrozil, increases exposure (both Cmax and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer, rifampin, decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8 [see Warnings and Precautions (5.3)].

Drug interaction studies have been carried out with treprostinil (oral or subcutaneous) co-administered with acetaminophen (4 g/day), warfarin (25 mg/day), and fluconazole (200 mg/day), respectively, in healthy volunteers. These studies did not show a clinically significant effect on the pharmacokinetics of treprostinil. Treprostinil does not affect the pharmacokinetics or pharmacodynamics of warfarin. The pharmacokinetics of R- and S- warfarin and the international normalized ratio (INR) in healthy subjects given a single 25 mg dose of warfarin were unaffected by continuous subcutaneous infusion of treprostinil at an infusion rate of 10 ng/kg/min.

Risk Summary Limited case reports of treprostinil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. However, there are risks to the mother and the fetus associated with pulmonary arterial hypertension (see Clinical Considerations). In animal studies, no adverse reproductive and developmental effects were seen for treprostinil at ≥9 and ≥145 times the human exposure when based on Cmax and AUC, respectively, following a single treprostinil dose of 54 mcg. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Clinical Considerations

Disease-associated maternal and embryo-fetal risk Pulmonary arterial hypertension is associated with an increased risk of maternal and fetal mortality.

Data Animal reproduction studies have been conducted with treprostinil via continuous subcutaneous administration and with treprostinil diolamine administered orally. In studies with orally administered treprostinil diolamine, no adverse effect doses for fetal viability/growth, fetal development (teratogenicity), and postnatal development were determined in rats. In pregnant rats, no evidence of harm to the fetus was observed following oral administration of treprostinil diolamine at the highest dose tested (20 mg/kg/day), which represents about 154 and 1479 times the human exposure, when based on Cmax and AUC, respectively, following a single Tyvaso dose of 54 mcg. In pregnant rabbits, external fetal and soft tissue malformations and fetal skeletal malformation occurred. The dose at which no adverse effects were seen (0.5 mg/kg/day) represents about 9 and 145 times the human exposure, when based on Cmax and AUC, respectively, following a single Tyvaso dose of 54 mcg. No treprostinil treatment-related effects on labor and delivery were seen in animal studies. Animal reproduction studies are not always predictive of human response.

Risk Summary There are no data on the presence of treprostinil in human milk, the effects on the breastfed infant, or the effects on milk production.

Safety and effectiveness in pediatric patients have not been established. Clinical studies of Tyvaso did not include patients younger than 18 years to determine whether they respond differently from older patients.

Across clinical studies used to establish the effectiveness of Tyvaso in patients with PAH and PH-ILD, 268 (47.8%) patients aged 65 years and over were enrolled. The treatment effects and safety profile observed in geriatric patients were similar to younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of hepatic, renal, or cardiac dysfunction, and of concomitant diseases or other drug therapy.

Plasma clearance of treprostinil, delivered subcutaneously, was reduced up to 80% in subjects with mild-to-moderate hepatic insufficiency. Uptitrate slowly when treating patients with hepatic insufficiency because of the risk of an increase in systemic exposure which may lead to an increase in dose-dependent adverse effects. Treprostinil has not been studied in patients with severe hepatic insufficiency [see Clinical Pharmacology (12.3)].

No dose adjustments are required in patients with renal impairment. Treprostinil is not cleared by dialysis [see Clinical Pharmacology (12.3)].

In general, symptoms of overdose with Tyvaso include flushing, headache, hypotension, nausea, vomiting, and diarrhea. Provide general supportive care until the symptoms of overdose have resolved.

Tyvaso is a sterile formulation of treprostinil, a prostacyclin mimetic, intended for administration by oral inhalation using the Tyvaso Inhalation System. Tyvaso is supplied in 2.9 mL low density polyethylene (LDPE) ampules, containing 1.74 mg treprostinil (0.6 mg/mL). Each ampule also contains 18.9 mg sodium chloride, 18.3 mg sodium citrate dihydrate, 0.58 mg sodium hydroxide, 11.7 mg 1 N hydrochloric acid, and water for injection. Sodium hydroxide and hydrochloric acid may be added to adjust pH between 6.0 and 7.2. Treprostinil is (1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl]oxy]acetic acid. Treprostinil has a molecular weight of 390.52 and a molecular formula of C23H34O5. The structural formula of treprostinil is: Chemical Structure

Treprostinil is a prostacyclin analogue. The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation.

In a clinical trial of 240 healthy volunteers, single doses of Tyvaso 54 mcg (the target maintenance dose per session) and 84 mcg (supratherapeutic inhalation dose) prolonged the corrected QTc interval by approximately 10 ms. The QTc effect dissipated rapidly as the concentration of treprostinil decreased.

Pharmacokinetic information for single doses of inhaled treprostinil was obtained in healthy volunteers in 3 separate studies. Treprostinil systemic exposure (AUC and C_max) post-inhalation was shown to be proportional to the doses administered (18 mcg to 90 mcg).

Absorption In a 3-period crossover study, the bioavailability of 2 single doses of Tyvaso (18 mcg and 36 mcg) was compared with that of intravenous treprostinil in 18 healthy volunteers. Mean estimates of the absolute systemic bioavailability of treprostinil after inhalation were approximately 64% (18 mcg) and 72% (36 mcg). Treprostinil plasma exposure data were obtained from 2 studies at the target maintenance dose, 54 mcg. The mean Cmax at the target dose was 0.91 and 1.32 ng/mL with corresponding mean Tmax of 0.25 and 0.12 hr, respectively. The mean AUC for the 54-mcg dose was 0.81 and 0.97 hr∙ng/mL, respectively.

Distribution Following parenteral infusion, the apparent steady state volume of distribution (Vss) of treprostinil is approximately 14 L/70 kg ideal body weight. In vitro treprostinil is 91% bound to human plasma proteins over the 330 to 10,000 mcg/L concentration range.

Metabolism and Excretion Of subcutaneously administered treprostinil, only 4% is excreted unchanged in urine. Treprostinil is substantially metabolized by the liver, primarily by CYP2C8. Metabolites are excreted in urine (79%) and feces (13%) over 10 days. Five apparently inactive metabolites were detected in the urine, each accounting for 10 to 15% of the dose administered. Four of the metabolites are products of oxidation of the 3-hydroxyloctyl side chain and 1 is a glucuroconjugated derivative (treprostinil glucuronide). The elimination of treprostinil (following subcutaneous administration of treprostinil) is biphasic, with a terminal elimination half-life of approximately 4 hours using a 2-compartment model.

Specific Populations

Hepatic Insufficiency Plasma clearance of treprostinil, delivered subcutaneously, was reduced up to 80% in subjects presenting with mild-to-moderate hepatic insufficiency. Treprostinil has not been studied in patients with severe hepatic insufficiency [see Use in Specific Populations (8.6)].

Renal Impairment In patients with severe renal impairment requiring dialysis (n=8), administration of a single 1 mg dose of orally administered treprostinil pre- and post-dialysis resulted in AUC0-inf that was not significantly altered compared to healthy subjects [see Use in Specific Populations (8.7)].

A 2-year rat carcinogenicity study was performed with treprostinil inhalation at target doses of 5.26, 10.6, and 34.1 mcg/kg/day. There was no evidence for carcinogenic potential associated with treprostinil inhalation in rats at systemic exposure levels up to 35 times the clinical exposure at the target maintenance dose of 54 mcg. In vitro and in vivo genetic toxicology studies did not demonstrate any mutagenic or clastogenic effects of treprostinil. Treprostinil sodium did not affect fertility or mating performance of male or female rats given continuous subcutaneous infusions at rates of up to 450 ng treprostinil/kg/min. In this study, males were dosed from 10 weeks prior to mating and through the 2-week mating period. Females were dosed from 2 weeks prior to mating until gestational day 6. Oral administration of treprostinil diolamine to Tg.rasH2 mice at 0, 5, 10, and 20 mg/kg/day in males and 0, 3, 7.5, and 15 mg/kg/day in females daily for 26 weeks did not significantly increase the incidence of tumors. Treprostinil diolamine was tested in vivo in a rat micronucleus assay and did not induce an increased incidence of micronucleated polychromatic erythrocytes.

In a 2-year rat study with treprostinil inhalation at target doses of 5.26, 10.6, and 34.1 mcg/kg/day, there were more deaths (11) in the mid- and high-dose treprostinil groups during the first 9 weeks of the study, compared to 1 in control groups. At the high-dose level, males showed a higher incidence of inflammation in teeth and preputial gland, and females showed higher incidences of inflammation and urothelial hyperplasia in the urinary bladder. The exposures in rats at mid- and high-dose levels were about 15 and 35 times, respectively, the clinical exposure at the target maintenance dose of 54 mcg.

TRIUMPH I, was a 12-week, randomized, double-blind, placebo-controlled, multicenter study of patients with PAH. The study population included 235 clinically stable subjects with PAH (WHO Group 1), nearly all with NYHA Class III (98%) symptoms who were receiving either bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase-5 inhibitor) for at least 3 months prior to study initiation. Concomitant therapy also could have included anticoagulants, other vasodilators (e.g., calcium channel blockers), diuretics, oxygen, and digitalis, but not a prostacyclin. These patients were administered either placebo or Tyvaso in 4 daily treatment sessions with a target dose of 9 breaths (54 mcg) per session over the course of the 12-week study. Patients were predominately female (82%), had the origin of PAH as idiopathic/heritable (56%), secondary to connective tissue diseases (33%) or secondary to HIV or previous use of anorexigens (12%); bosentan was the concomitant oral medication in 70% of those enrolled, sildenafil in 30%. The primary efficacy endpoint of the trial was the change in 6-Minute Walk Distance (6MWD) relative to baseline at 12 weeks. 6MWD was measured at peak exposure (between 10 and 60 minutes after dosing), and 3 to 5 hours after bosentan or 0.5 to 2 hours after sildenafil. Patients receiving Tyvaso had a placebo-corrected median change from baseline in peak 6MWD of 20 meters at Week 12 (p<0.001). The distribution of these 6MWD changes from baseline at Week 12 were plotted across the range of observed values (Figure 1). 6MWD measured at trough exposure (defined as measurement of 6MWD at least 4 hours after dosing) improved by 14 meters. There were no placebo-controlled 6MWD assessments made after 12 weeks. Figure 1: Distributions of 6MWD Changes from Baseline at Week 12 During Peak Plasma Concentration of Tyvaso The placebo-corrected median treatment effect on 6MWD was estimated (using the Hodges-Lehmann estimator) within various subpopulations defined by age quartile, gender, geographic region of the study site, disease etiology, baseline 6MWD quartile, and type of background therapy (Figure 2). Figure 2: Placebo-Corrected Median Treatment Effect (Hodges-Lehmann Estimate with 95% CI) on 6MWD Change from Baseline at Week 12 During Peak Plasma Concentration of Tyvaso for Various Subgroups Figure 1 Figure 2

In long-term follow-up of patients who were treated with Tyvaso in the pivotal study and the open-label extension (N=206), Kaplan-Meier estimates of survival at 1, 2, and 3 years were 97%, 91%, and 82%, respectively. These uncontrolled observations do not allow comparison with a control group not given Tyvaso and cannot be used to determine the long-term effect of Tyvaso on mortality.

INCREASE was a 16-week, randomized, double-blind, placebo-controlled, multicenter study that enrolled 326 patients with PH-ILD. Enrolled study patients predominately had etiologies of idiopathic interstitial pneumonia (45%) inclusive of idiopathic pulmonary fibrosis, combined pulmonary fibrosis and emphysema (25%), and WHO Group 3 connective tissue disease (22%). The mean baseline 6MWD was 260 meters. Patients in the INCREASE study were randomized (1:1) to either placebo or Tyvaso in 4 daily treatment sessions with a target dose of 9 breaths (54 mcg) per session and a maximum dose of 12 breaths (72 mcg) per session over the course of the 16-week study. Approximately 75% of patients randomized to Tyvaso titrated up to a dose of 9 breaths, 4 times daily or greater, with 48% of patients randomized to Tyvaso reaching a dose of 12 breaths, 4 times daily during the study. The primary efficacy endpoint was the change in 6MWD measured at peak exposure (between 10 and 60 minutes after dosing) from baseline to Week 16. Patients receiving Tyvaso had a placebo-corrected median change from baseline in peak 6MWD of 21 meters at Week 16 (p=0.004) using Hodges-Lehmann estimate (Figure 3). Figure 3: Hodges-Lehmann Estimate of Treatment Effect by Visit for 6MWD at Peak Exposure (PH-ILD) The treatment effect on 6MWD at Week 16 was consistent for various subgroups, including etiology of PH-ILD, disease severity, age, sex, baseline hemodynamics, and dose (Figure 4). Figure 4: Forest Plot on Subgroup Analyses of Peak 6MWD (Meter) at Week 16 (PH-ILD) Time to clinical worsening in the INCREASE study was defined as the time of randomization until 1 of the following criteria were met: hospitalization due to a cardiopulmonary indication, decrease in 6MWD >15% from baseline directly related to PH-ILD at 2 consecutive visits and at least 24 hours apart, death (all causes), or lung transplantation. Treatment with Tyvaso in patients with PH-ILD resulted in numerically fewer hospitalizations. The numbers of reported deaths were the same for both treatment groups (Table 2). Overall, treatment with Tyvaso demonstrated a statistically significant increase in the time to first clinical worsening event (log-rank test p=0.041; Figure 5), and a 39% overall reduction in the risk of a clinical worsening event (HR=0.61 [95% CI; 0.40, 0.92]; Figure 5).

Table 2: Clinical Worsening Events (PH-ILD)

		Tyvaso n=163 n (%)	Placebo n=163 n (%)	HR (95% CI)
Clinical worsening		37 (22.7%)	54 (33.1%)	0.61 (0.40, 0.92)
First contributing event	Hospitalization due to a cardiopulmonary indication	18 (11.0%)	24 (14.7%)
	Decrease in 6MWD >15% from baseline directly related to PH-ILD	13 (8.0%)	26 (16.0%)
	Death (all causes)	4 (2.5%)	4 (2.5%)
	Lung transplantation	2 (1.2%)	0
First of each event	Hospitalization due to a cardiopulmonary indication	21 (12.9%)	30 (18.4%)
	Decrease in 6MWD >15% from baseline directly related to PH-ILD	16 (9.8%)	31 (19.0%)
	Death (all causes)	8 (4.9%)	10 (6.1%)
	Lung transplantation	2 (1.2%)	1 (0.6%)

Figure 5: Kaplan-Meier Plot of Time to Clinical Worsening Events (PH-ILD) Figure 3 Figure 4 Figure 5

Tyvaso (treprostinil) inhalation solution is supplied in 2.9 mL clear LDPE ampules packaged as 4 ampules in a foil pouch. Tyvaso is a clear colorless to slightly yellow solution containing 1.74 mg treprostinil per ampule at a concentration of 0.6 mg/mL.

Ampules of Tyvaso are stable until the date indicated when stored in the unopened foil pouch at 20-25°C (68-77°F) with excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Once the foil pack is opened, ampules should be used within 7 days. Because Tyvaso is light-sensitive, unopened ampules should be stored in the foil pouch. One ampule of Tyvaso should be used each day in the Tyvaso Inhalation System. After a Tyvaso ampule is opened and transferred to the medicine cup, the solution should remain in the device for no more than 1 day (24 hours). Any remaining solution should be discarded at the end of the day. Tyvaso Inhalation System Starter Kit containing a 28-ampule carton of Tyvaso (7 foil pouches each containing four 2.9 mL ampules; each ampule contains 1.74 mg treprostinil [0.6 mg per mL]) and the Tyvaso Inhalation System. (NDC 66302-206-01) Tyvaso Inhalation System Refill Kit containing a 28-ampule carton of Tyvaso (7 foil pouches each containing four 2.9 mL ampules; each ampule contains 1.74 mg treprostinil [0.6 mg per mL]) and accessories. (NDC 66302-206-02) Tyvaso 4 Pack Carton with 1 foil pouch containing four 2.9 mL ampules. Each ampule contains 1.74 mg treprostinil (0.6 mg per mL). (NDC 66302-206-03) Tyvaso Inhalation System Institutional Starter Kit containing a 4-ampule carton of Tyvaso (1 foil pouch containing four 2.9 mL ampules; each ampule contains 1.74 mg treprostinil [0.6 mg per mL]) and the Tyvaso Inhalation System. (NDC 66302-206-04)

Advise the patient to read the FDA-approved patient labeling (Instructions for Use). Train patients in the administration process for Tyvaso, including dosing, Tyvaso Inhalation System set up, operation, cleaning, and maintenance, according to the instructions for use [see Dosage and Administration (2.1, 2.2)]. To avoid potential interruptions in drug delivery because of equipment malfunction, patients should have access to a back-up Tyvaso Inhalation System device [see Dosage and Administration (2.2)]. In the event that a scheduled treatment session is missed or interrupted, resume therapy as soon as possible [see Dosage and Administration (2.1)]. If Tyvaso comes in contact with the skin or eyes, instruct patients to rinse immediately with water [see Dosage and Administration (2.2)].

©Copyright 2022 United Therapeutics Corp. All rights reserved. Tyvaso manufactured for: United Therapeutics Corp.
Research Triangle Park, NC 27709

TYVASO ^®
INHALATION SYSTEM Instructions for Use Manual TYVASO ^®
(treprostinil)
INHALATION
SOLUTION Contents

Overview of your TYVASO Inhalation System	4
Introduction	6
Safety and general instructions	8
Buttons, indicators, and markings	10
Inhalation device display screens	16
Programming your TYVASO Inhalation System before use	18
Charging device before use	20
Setting your prescribed dose	22
Adjusting device's audio volume	24
Preparing and using your TYVASO Inhalation System for daily treatments	26
Prepare a proper environment	28
Gather supplies	29
Fill water chamber and medicine cup	32
Assemble inhalation device	35
Power on inhalation device	40
Inhale your medicine	42
Cleaning and Storing your TYVASO Inhalation System	46
Storing between sessions during the day	48
End of day cleaning	52
Recharging the battery	57
Weekly cleaning	59
Monthly Refill Kit	60
Replacing your devices	61
Help / More information about your TYVASO Inhalation System	62
Troubleshooting	64
Specifications	76
Electromagnetic compatibility (EMC)	79
Glossary	87
Warranty information	90

Overview of your TYVASO Inhalation System Section overview This section introduces you to your TYVASO Inhalation System and provides important safety information about using your system.

What you will need:
▶ A clean place to review these instructions
▶ TYVASO Inhalation System to refer to while reading instructions

What is covered in this section:
A: Introduction	6
B: Safety and general instructions	8
C: Buttons, indicators, and markings	10
D: Inhalation device display screens	16

Important: Do not start treatment with TYVASO until you have been trained to use the TYVASO Inhalation System. Make sure you understand all of the directions. Always ask your doctor or specialty pharmacy provider if you have any questions or are unsure of anything you are taught.

A: Introduction

Your doctor has prescribed TYVASO^® (treprostinil) Inhalation Solution. Please see the accompanying Prescribing Information for important safety information on TYVASO. TYVASO is breathed in (inhaled) using the TYVASO Inhalation System, which consists of the inhalation device and its accessories. This Instructions for Use manual for the TYVASO Inhalation System provides important safety information. It is important that you read these instructions and the TYVASO Prescribing Information before setting up and using the TYVASO Inhalation System. If you have any questions, talk to your doctor or specialty pharmacy provider. Before beginning treatment with TYVASO, you will receive either a Patient Starter Kit containing a 28-day supply of TYVASO or an Institutional Starter Kit containing a 4-day supply of medication. Both kits include 2 complete inhalation devices (all accessories and supplies included). When you refill your prescription for TYVASO each month, you will receive a Refill Kit that contains a 28-day supply of TYVASO and new accessories. You will receive replacement devices every 2 years from your date of receipt of the TYVASO Inhalation System.  CAUTION: Federal law restricts this device to sale by or on the order of a physician, or other licensed practitioner. Important: Keep this Instructions for Use manual in a safe place where you can easily get to it for reference. For example, store the booklet in the TYVASO Inhalation System carrying case, along with your other supplies. TYVASO Inhalation System is intended solely for the delivery of TYVASO (treprostinil) Inhalation Solution. TYVASO is for administration only with the TYVASO Inhalation System.

B: Safety and general instructions

The TYVASO Inhalation System should be handled carefully. Take the following precautions and follow all instructions in this document to avoid injury and ensure proper use: Delivering treatments: Read the instructions carefully and completely to prevent damage to your TYVASO Inhalation System and help you get the best results. This device should only be used on the order of your doctor or licensed healthcare practitioner. Conduct only the number of treatment sessions and inhalations you have been prescribed. Ensure the breath counter is correctly programmed prior to beginning a treatment (see page 22). Turn off the device when not in use. Do not use the device with an anesthetic breathing system or ventilator breathing system. Use only the supplies provided in the Starter Kit and Monthly Refill Kit for correct device function. Handling the device: Do not peel or remove the labels from the device. Do not drop the device. The device does not include internal, replaceable parts. Do not attempt to open the device, modify the device, or remove device labeling. Your environment: Do not leave the device alone with a small child. Do not immerse the device in water or other liquids, or place in dishwasher. Do not place any system components in a microwave, conventional oven, or dishwasher. Do not use the device near flammable liquids and materials or heated surfaces. Do not place the device or use the device in the presence of strong electric or magnetic fields (e.g., microwave oven, magnetic imaging equipment). Wireless communications equipment (e.g., cell phone) can affect operation of the device and should be kept at least a distance of 3.3 meters (about 11 feet) away while using the device. If the device performance is affected by exposure to any conditions listed here, see the Troubleshooting section, or contact your healthcare provider or specialty pharmacy provider.

C: Buttons, indicators, and markings

Inhalation device Inhalation indicator lights Lights on top of device flash green when you should inhale. On/Off, Start/Pause (blue) button Press and hold to power device on or off. Once device is on, press and immediately release (do not hold down) to start or pause treatment. Device Display Provides instructions and device information. Run / Program switch Slide up to Run mode when you are ready to deliver your dose. Slide down to Program mode to program the number of breaths for your dose. Volume / Breaths toggle button When set to Run mode, push + to increase beeping volume, or push - to decrease beeping volume. When set to Program mode, push + to increase the number of breaths, or push - to decrease the number of breaths required for each dose. Power status light Lights green when power is connected and battery is charging. Power port Port for plugging into a power source using the AC wall plug.

Additional device markings
	Manufacturer. Indicates the medical device manufacturer. (Symbol 5.1.1 of ANSI/AAMI/ISO 15223-1: 2012 Medical devices - symbols to be used with medical devices labels, labeling, and information to be supplied - part 1: general requirements)
	Equipment should not be disposed of in the trash. (Figure 1 of BS EN 50419:2006 - Marking of Electrical and Electronic Equipment in accordance with Article 11(2) of Directive 2002/96/EC (WEEE))
	Catalogue number. Indicates the manufacturer's catalogue number so that the medical device can be identified. (Symbol 5.1.6 of ANSI/AAMI/ISO 15223-1: 2012 Medical devices - symbols to be used with medical devices labels, labeling, and information to be supplied - part 1: general requirements)
	Serial number. Indicates the manufacturer's serial number so that a specific medical device can be identified. (Symbol 5.1.7 of ANSI/AAMI/ISO 15223-1: 2012 Medical devices - symbols to be used with medical devices labels, labeling, and information to be supplied - part 1: general requirements)
	Consult instructions for use. Please read the accompanying instructions and labels for important information regarding the TYVASO Inhalation System. (Symbol 5.4.3 of ANSI/AAMI/ISO 15223-1: 2012 Medical devices - symbols to be used with medical devices labels, labeling, and information to be supplied - part 1: general requirements)
	The TYVASO Inhalation System has a Type BF Applied part. Type BF Applied parts comply with specific requirements to provide protection against shock and are not suitable for direct cardiac applications. (Symbol 5333 of IEC 60417 Database Snapshot - Graphical symbols for use on equipment)
	The TYVASO Inhalation System requires a 14V DC power supply. Use only the power supply intended for the TYVASO Inhalation System. (Direct Current, Symbol 5031 of IEC 60417 Database Snapshot - Graphical symbols for use on equipment)
	The TYVASO Inhalation System complies with the requirements of Protection Class II. Class II equipment provides additional precautions, over and above basic insulation, to provide protection against electric shock. (Class II equipment, Symbol 5172 of IEC 60417 Database Snapshot - Graphical symbols for use on equipment)
	The TYVASO Inhalation Device provides level 2 solid particle protection and level 2 liquid ingress protection per IEC 60529 specifications.
	The TYVASO Inhalation System should only be used on the order of your doctor or licensed healthcare provider. (Symbol statement as provided under 21 CFR 801.109(b)(1))
	Power stand by. Indicates the control for powering on and off the TYVASO Inhalation System. ("On" / "Off", Symbol 5010 of IEC 60417 Database Snapshot - Graphical symbols for use on equipment)
	Start/Pause. Indicates the control for starting a treatment session once the device is powered on, and for pausing a treatment once a treatment session has started. (Play and Pause, Symbols 5107B and 5111B, respectively, of IEC 60417 Database Snapshot - Graphical symbols for use on equipment)

D: Inhalation device display screens
Splash screen Device name and software version	Last Treatment Time since your last treatment	Program Breaths Number of breaths set in Program mode	Adjust Volume Audio volume level set in Run mode
Breaths Left Number of breaths left in a current dose	Exhale Prompt to exhale during a dose	Inhale Prompt to inhale during a dose	Done Treatment session is complete
Pause You have paused a treatment session	Call Support Device is not working, call your specialty pharmacy provider for support
Add Water Wrong or missing fluid in water chamber	Charge Battery Battery not charged enough to deliver treatment	Status icons Icons that might appear at bottom of the screen

Programming your TYVASO Inhalation System before use Section overview This section provides instructions for charging your device, setting your dose, and adjusting the device's audio volume before you use the device for a treatment.

What you will need:
▶ A clean place to work with the device
▶ TYVASO Inhalation Device
▶ The number of breaths your doctor prescribed for each dose

What is covered in this section:
A: Charging device before use	20
B: Setting your prescribed dose	22
C: Adjusting device's audio volume	24

Important: Do not start treatment with TYVASO until you have been trained to use the TYVASO Inhalation System. Make sure you understand all of the directions. Always ask your doctor or specialty pharmacy provider if you have any questions or are unsure of anything you are taught.

A: Charging device before use

1. Plug in device Important: A new device might not be fully charged when you receive it. Always charge the device before you first use it. You can also charge the device overnight, when not in use and in between uses. Plug the AC wall plug's white connector into the port on the back of the inhalation device. Then, plug the AC wall plug into the wall outlet. The power status light above the port will light green when properly plugged in. 2. Check the battery's status Make sure the Run / Program switch is set to Run. Press and hold the blue button to power on the device. The battery icon at the bottom of the screen indicates battery status. When you are done checking the battery status, press and hold the On/Off button until the display screen shuts off (note: letting the button go before the screen shuts off will start a treatment session).

If there is not enough charge to conduct a treatment session, "Charge battery" appears on screen.

B: Setting your prescribed dose

Your doctor will prescribe the number of breaths you should take in each treatment session. You should program this number into the inhalation device before you use the device. 1. Switch to Program Slide the Run / Program switch on the side of the device down to Program mode. In Program mode you enter the prescribed number of breaths for each dose. You cannot begin a treatment in Program mode. 2. Power on Press and hold the On/Off button until the display screen turns on. The Program Breaths screen appears. The number of breaths currently set for each treatment session will flash. 3. Set breaths Use the Volume / Breaths toggle button to enter your prescribed number of breaths onto the program screen. 4. Switch to Run Slide the Run / Program switch up to Run mode. Make sure your new breath count appears on screen. 5. Power off Press and hold the On/Off button until the display screen shuts off (note: letting the button go before the screen shuts off will start a treatment session). Note: You will not need to program the breath count again, unless your prescribed number of breaths changes.

C: Adjusting device's audio volume

You can use the Volume / Breaths toggle button to adjust the volume of the audible signals (beeps) that the device provides as feedback during treatment sessions. 1. Switch to Run Slide the Run / Program switch up to Run mode, if it is not in this position already. 2. Power on Press and hold the On/Off button until the display screen turns on, if it is not already turned on. The programmed number of breaths will appear with the words "Breaths left" and the battery icon at the bottom. 3. Adjust volume With the Run / Program switch in the Run position, press the Volume / Breaths toggle button to access the Adjust Volume screen. Push + on the Volume / Breaths toggle button to increase beeping volume, or push - to decrease beeping volume.

audio off	mid-level volume	maximum volume

4. Power off After adjusting the beeping volume up or down, the screen will display your new setting for a couple of seconds then return to the screen displaying the breaths left. Press and hold the On/Off button until the display screen shuts off (note: letting the button go before the screen shuts off will start a treatment session). Preparing and using your TYVASO Inhalation System for daily treatments Section overview This section provides instructions for preparing and using your TYVASO Inhalation System for daily treatments.

What you will need:
▶ A clean place to take your medicine
▶ TYVASO Inhalation device
▶ TYVASO Inhalation supplies
▶ One ampule of TYVASO Inhalation Solution

What is covered in this section:
A: Prepare a proper environment	28
B: Gather supplies	29
C: Fill water chamber and medicine cup	32
D: Assemble inhalation device	35
E: Power on inhalation device	40
F: Inhale your medicine	42

Important: Before using the TYVASO Inhalation System, you should: Wash your hands. Make sure the device is resting on a stable, flat surface during assembly.

A: Prepare a proper environment

Follow these important instructions before setting up your treatment: Use the device in a quiet, distraction-free area. Try to use the device at times when your treatment will not be interrupted. If needed, you can pause your treatment (see page 44). Use the device in a comfortable space where you can stand or sit in an upright position. Use the device in an area where you can access a power source if you need to use the AC wall plug. The TYVASO Inhalation System is recommended for use indoors. Use the device in an area that provides enough space for the TYVASO Inhalation System and its accessories. Gather all necessary supplies on a stable, flat surface for assembly (see page 29 for list of supplies). Store the inhalation device at 15°C to 30°C (59°F to 86°F). Use at 15°C to 25°C (59°F to 77°F). Use the device in a well-lit area where you can clearly read these instructions, labels on the device, and the device screen.

B: Gather supplies

Gather the following supplies before starting treatment. Use only the supplies provided in the starter kit and monthly refill kit for correct device function. Prior to use, inspect each part and do not use parts if they appear damaged or dirty.

Inhalation device Powered off	TYVASO ampules Use 1 ampule per day	Water level cup with 45 mL of distilled water
Filter membranesThese accessories are replaced every month. Replacement accessories are included in the Monthly Refill Kit. Use 2 per day	Medicine cups Use 1 per day	Dome assembly
Mouthpiece	Inhalation piece	2 filter shells
2 Plugs (Used when storing the device)	Carrying case	Pen or pencil (not provided) to record your treatment
Distilled water carrier	AC wall plug	Treatment Tracker Example

C: Fill water chamber and medicine cup

Important: Wash your hands
Unplug device when filling to avoid damage to cords or connectors. Only use distilled water in the device. Distilled water is highly purified water that is required for the device to function properly. If you use another type of water (such as bottled or tap water), the device might not function properly. You can purchase distilled water at most grocery stores and pharmacies. 1. Fill water chamber Fill the water level cup with distilled water up to the arrow markers on the water cup. Use fresh distilled water each day (i.e., do not use water left in the water chamber from the previous day). Pour the distilled water into the water chamber. Make sure the water level is above the upper, silver sensor and below the blue ring in the water chamber (about 45 mL of distilled water). Do not overfill the water chamber, or else the medicine cup might not fit correctly. 2. Place medicine cup Obtain 1 new medicine cup and inspect it. Do not use a medicine cup that is damaged (e.g., cracked or contains holes or dents), dirty, or was used before. Place the empty medicine cup into the water chamber of the device, making sure that the cup's bottom tip is in the distilled water.  CAUTION: Make sure you place only 1 medicine cup. Placing multiple cups will prevent the flow of medicine. 3. Gather one ampule Carefully cut open the top of the foil pouch, making sure not to cut the ampules. Each pouch contains 4 ampules. Remove 1 ampule of TYVASO. Keep unused ampules in the foil pouch because the TYVASO medicine is sensitive to light. Write the date you first opened the pouch on the foil pouch. One ampule contains enough medicine for 1 day of treatment no matter how many breaths your doctor has prescribed.  CAUTION: Ampules must be used within 7 days of opening foil pouch. Open only 1 pouch at a time. Throw away (discard) any unused ampules after 7 days. 4. Open ampule Gently hold the ampule in the upright (top up) position and twist off its top.  CAUTION: If any medicine from the ampule spills on your hands, wash your hands right away. Medicine contact with the skin can cause irritation. 5. Squeeze ampule Point the ampule straight down toward the medicine cup's center to avoid spills. Gently squeeze the medicine out of the ampule into the medicine cup. Squeeze until it is empty. Check to see that all of the medicine is in the medicine cup.

D: Assemble inhalation device

Important: Do not force parts together. The TYVASO Inhalation System is designed so the parts only fit together properly one way. When the device is assembled correctly, the parts should fit together easily. 1. Check dome assembly Visually check to make sure the black ring is securely placed in the dome assembly. The black ring should look like it does in the pictures below. If the black ring is loose or missing, do not use the dome assembly. Throw it away and get a new one. If you need to order a new dome assembly, contact your specialty pharmacy provider. 2. Attach dome assembly Align the raised circle on the side of the dome assembly with the raised circle on the side of the device. Push down and screw the dome assembly onto the device clockwise (right) until the filter shell port is tight and pointed to the back of the device. You will hear clicks (or a slight crunching sound) as the dome assembly presses down on the medicine cup. Important: The dome assembly "clicks" only the first time it connects to the medicine cup. If you then realign the dome assembly you will not hear another click. 3. Install new filter membrane Each day you will need to use a new filter membrane in each filter shell. Note: New filter shells come with fresh filter membranes already installed.

To install a new filter membrane:

▶ a. Open the filter shell by unscrewing the 2 halves.

▶ b. Place a new filter membrane in 1 of the filter shell halves.

▶ c. Close the filter shell by screwing the 2 halves together until you can twist no further.

▶ d. Repeat steps a-c for second filter shell.

4. Attach filter shells Insert 1 filter shell into the filter shell port on the side of the dome assembly and insert the second filter shell into the port on the bottom of the inhalation piece. The filter shells are the same and can be used in either port. You can turn the filter shells around to fit into the ports, as needed. Make sure to insert filter shells straight into ports, not at an angle. 5. Insert inhalation piece Insert the inhalation piece with attached filter shell into the upper opening of the dome assembly and turn it toward the front of the device. Gently push down the inhalation piece to make sure it is securely inserted in the dome assembly. 6. Insert mouthpiece Carefully insert the mouthpiece into the inhalation piece. 7. Check assembled device When the device is fully assembled, it should look like it does below. Slightly turn the inhalation piece so you can see the display screen, which provides important prompts during your treatment. Important: Do not use device if you see liquid leaking from bottom of the device.

E: Power on inhalation device

1. Power on device Press and hold the On/Off button until the screen turns on and the device beeps once. The screen will display the splash screen, then the time since your last treatment, then the current breaths programmed for each dose. Important: Make sure the number on screen above "Breaths left" matches the prescribed number of breaths for that treatment session. If it does not match, see page 22 for instructions on setting the number of breaths for a treatment session. 2. Plug in device, if needed If the device's internal battery is too low to deliver a full treatment, the screen will display an instruction to plug in the power to charge the device battery. If the battery is fully depleted, the screen will not turn on. You can charge the battery at any time, before the screen displays "Charge battery." You can conduct a treatment session with the power plugged in. First, plug the AC wall plug's white connector into the port on the back of the inhalation device. Then, plug the AC wall plug into the wall outlet. The power status light above the port will light green when properly plugged in.

F: Inhale your medicine

1. Before starting, confirm treatment You will breathe in (inhale) TYVASO during 4 treatment sessions each day (evenly spaced during your waking hours). During each treatment session, you will take a series of breaths through the mouthpiece of the TYVASO Inhalation System. Before inhaling your medicine, ensure the Run/Program switch is in the 'Run' position, and make sure the number displayed on screen matches your prescribed number of breaths for that treatment session. During the treatment the device counts down each breath after a set time interval. Once you complete all breaths, record the breath number in your Treatment Tracker. Important: If the number of breaths displayed does not match the number of breaths in your prescription, see page 22 "Setting your prescribed dose" and repeat steps 1-4. 2. Hold the device upright Hold the device upright and stand or sit in an upright position as shown below. Avoid covering the bottom of the device so that the audio speaker is not blocked. Make sure you can see the display screen and lights clearly and that your hands do not cover the display screen or lights while holding device. If needed, you can move the inhalation piece and mouthpiece slightly to either side to see the screen and lights better. See next page to start treatment. Inhalation tips: Technique: When breathing each TYVASO treatment, be sure to keep the device level, directing the flow of medicine into the throat and not toward the roof of the mouth. Seal your lips around the mouthpiece to ensure that you can inhale the full amount of TYVASO after it is produced by the device. Inhalation: Each breath should last approximately 3 seconds, breathing "normal full breaths." Do not hold your breath. Remove your lips from the mouthpiece, breathe out (exhale) normally and prepare for the next breath. 3. Press blue button to start treatment If you need to pause treatment, you can press and immediately release (do not hold down) the blue button. Press the button again and immediately release to resume treatment. (Note: If you do not resume treatment after pausing, power off device.) 4. Wait Look at the display screen for cues. Wait until you hear 2 short beeps. When you hear 1 long beep, exhale to prepare to inhale. 5. Inhale When you hear 1 short beep and the indicator lights flash green, place your lips securely around the mouthpiece and inhale for 3 seconds. When lights stop flashing, remove lips from mouthpiece and exhale normally. 6. Repeat for each breath left The screen will decrease the number of breaths left by 1. Repeat steps 4 and 5 for the number of prescribed breaths. 7. Finish session After displaying the last breath sequence, the green Done screen appears, you will hear a beep, and your treatment is done. If the device is left in the "✓ Done" mode for more than 60 seconds, it will turn off automatically. 8. Record breaths, turn off device Record the number of breaths you inhaled on the Treatment Tracker. Press and hold blue button until screen turns off.  CAUTION: If medicine does not appear to be flowing properly, the system might be set up incorrectly. See "Troubleshooting", starting on page 64 for details. Cleaning and Storing your TYVASO Inhalation System Section overview This section provides instructions for storing your TYVASO Inhalation System after each treatment and daily and weekly cleaning. There is also information about your monthly refill kits, replacing your device, and recharging the device's battery.

What you will need:
▶ A clean place to work with the device
▶ TYVASO Inhalation device
▶ TYVASO Inhalation supplies

What is covered in this section:
A: Storing between sessions during the day	48
B: End of day cleaning	52
C: Recharging the battery	57
D: Weekly cleaning	59
E: Monthly Refill Kit	60
F: Replacing your devices	61

Important: For further support, you can: Fill out and refer to your emergency contact information on the back of this Instructions for Use manual. Call 1-844-UNITHER (1-844-864-8437) for questions and information, or to report an adverse reaction.

A: Storing between sessions during the day

If you have more treatment sessions left in the day, perform the steps in this section. If you have completed your last treatment session of the day, skip to "End of day cleaning" on page 52. Be sure to pack all parts, including the AC wall plug, in the carrying case whenever transporting your device. 1. Disconnect AC wall plug
(if it is currently connected) 2. Remove mouthpiece 3. Remove inhalation piece Important: When removing accessories between treatment sessions, hold the device by its base to avoid spilling the medicine. 4. Remove both filter shells Note: Do not remove the filter membranes from filter shells until after the last treatment session of the day. 5. Leave dome assembly Leave dome assembly and medicine cup (with the medicine still in it) attached to the device. 6. Place plugs in dome assembly Insert a plug into each of the 2 open holes on the dome assembly to prevent the medicine from spilling out. Important: If the plugs are not in place, the medicine may spill. If you spill any medicine, discard remaining medicine and start your next treatment with a new ampule. 7. Store in carrying case You can store the inhalation device with the plugged dome assembly and disassembled accessories in the carrying case between treatment sessions. Keep the carrying case upright while inserting the device and components so that water and medicine does not spill out of the device. Important: Store the inhalation device in an upright position until the next treatment session. See "Specifications" on page 76 for additional storage and transport information.

B: End of day cleaning

If you have completed your last treatment session of the day, perform the steps in this section. If you have more treatment sessions left in the day, refer back to "Storing between sessions during the day" on page 48. 1. Disconnect AC wall plug
(if it is currently connected) 2. Remove mouthpiece 3. Remove inhalation piece with attached filter shell 4. Remove both filter shells 5. Discard filter membranes Open filter shells by twisting in opposite directions. Remove and discard used filter membranes in the trash. 6. Remove dome assembly Remove the dome assembly by turning it counter-clockwise (to the left). The medicine cup should stay attached to the dome assembly. 7. Remove medicine cup Remove the medicine cup by gently squeezing on the sides where it is attached to the dome assembly. Be careful not to spill any leftover medicine.  CAUTION: If any medicine from the medicine cup spills on your hands, wash your hands immediately. Medicine contact with the skin can cause irritation. 8. Empty medicine cup Empty any leftover medicine in the medicine cup into a waste basket, and discard the medicine cup. Important: Discard remaining TYVASO^® (treprostinil) Inhalation Solution in an appropriate waste receptacle. Discard plastic medicine cup in the trash. Do not reuse or recycle medicine cup. 9. Empty and clean device Empty distilled water from water chamber and let inhalation device air dry upside down. You can wipe the water chamber with a soft cloth or paper towel to remove any remaining water. Important: Do not place the inhalation device in water or in a dishwasher. 10. Clean accessories Clean accessories (pictured below) by hand in mild, soapy, warm water, then rinse them thoroughly with water. Allow accessories to air dry.

Dome assembly	Inhalation piece
Mouthpiece	Filter shells

Important: Do not place the inhalation device or its accessories in a microwave, conventional oven, or dishwasher. 11. Store components Once all the items are dry, you can store the filter shells, inhalation piece, mouthpiece, dome assembly, AC wall plug, and inhalation device in the carrying case until the next day's treatment sessions. You can also recharge the device for the next day of use (see page 57).

C: Recharging the battery

1. Checking the battery's status You can recharge your battery at any time. Press and hold the blue button to power on the device to check battery status. Make sure the Run / Program switch is set to Run. The battery icon at the bottom of the screen indicates battery status: "Charge battery" appears on screen if there is not enough charge to conduct a treatment session. Important: Always charge the device before you first use it. You should also charge the device when not in use and in between uses. 2. Charging the battery Plug the AC wall plug's white connector into the port on the back of the inhalation device. Then, plug the AC wall plug into the wall outlet. The power status light above the port will light green when properly plugged in. The device battery might take up to 8 hours to fully charge. If the device is powered on, the battery charging icon appears next to the battery icon at the bottom of the screen.

Battery charging icon

D: Weekly cleaning

Clean the device once a week to help avoid corrosion and leaks and to keep your device working properly. Once a week, use a clean, dry cloth to wipe the interior of the water chamber. Make sure to wipe the 2 silver sensors and the white disc in the bottom of the water chamber. You may wipe the exterior of the device with a damp cloth if the lights or buttons become difficult to see.

E: Monthly Refill Kit

Once a month, you will receive a refill kit that will come with a new set of accessories from your specialty pharmacy provider. Inspect the shipment to be sure all parts are included. Once the new kit has arrived, discard the used dome assembly, inhalation piece, mouthpiece, filter shells, and plugs. Do not recycle the used accessories.

Dome assembly	2 filter shells
Mouthpiece	Inhalation piece	2 plugs
Filter membranes	Medicine cups

F: Replacing your devices

The inhalation devices should be replaced every 2 years from your first day of use. Replacement inhalation devices will be supplied by your specialty pharmacy provider. When you receive a new inhalation device your specialty pharmacy provider will provide instructions for returning the old device. Help / More information about your TYVASO Inhalation System Section overview This section provides additional information about your device. Use this section to troubleshoot difficulties you have with the device, or to learn more about the device's specifications and warranty.

What you will need:
▶ Access to a phone (to contact support if troubleshooting steps do not resolve the problem)
▶ A clean place to work with the device
▶ TYVASO Inhalation Device or supplies, as needed

What is covered in this section:
A: Troubleshooting	64
B: Specifications	76
C: Electromagnetic compatibility (EMC)	79
D: Glossary	87
E: Warranty information	90

Important: For further support, you can: Fill out and refer to your emergency contact information on the back of this Instructions for Use manual. Call 1-844-UNITHER (1-844-864-8437) for questions and information, or to report an adverse reaction.

A: Troubleshooting

Problem	Possible causes	Corrective actions
Charge Battery screen appears	Low battery	Charge the device battery by attaching the AC wall plug to an outlet. You can conduct a treatment session with the device plugged in.
	AC wall plug not properly connected	Ensure that the plug adapter piece (the detachable piece with the metal prongs) is securely attached to the AC wall plug. Then, make sure the AC wall plug is properly connected to an outlet and device. The status lights on the back of the AC wall plug and device should light green. You can conduct a treatment session with the device plugged in.
	AC wall plug is defective	Use the replacement AC wall plug. Confirm that status light on AC wall plug is green when plugged in. You can conduct a treatment session with the device plugged in.
	If device still does not function after taking corrective actions listed above, contact your specialty pharmacy provider for assistance.
Screen does not turn on	Device battery is completely empty	Charge the device battery by attaching the AC wall plug to an outlet. You can conduct a treatment session with the device plugged in.
	AC wall plug not properly connected	Ensure that the plug adapter piece (the detachable piece with the metal prongs) is securely attached to the AC wall plug. Then, make sure the AC wall plug is properly connected to an outlet and device. The status lights on the back of the AC wall plug and device should light green. You can conduct a treatment session with the device plugged in.
	AC wall plug is defective	Use the replacement AC wall plug. Confirm that status light on AC wall plug is green when plugged in. You can conduct a treatment session with the device plugged in.
	If device still does not function after taking corrective actions listed above, contact your specialty pharmacy provider for assistance.
Call Support screen appears	Temporary device failure.	If device is plugged in, unplug device and wait for the device to power off. Power on device from internal battery and check that Call Support screen does not reappear. Continue taking breaths to complete the treatment session.
	If device still does not function after taking corrective actions listed above, contact your specialty pharmacy provider for assistance.
Loss of power during treatment	Device is disconnected from power source and battery is empty	Reconnect device to power source and confirm the power status light on back of device is green (battery is charging). Press and hold the blue On/Off button to turn on the device. The display will show how many breaths are left in that treatment session. Press and immediately release (do not hold down) the blue button again to continue your treatment session.
	Power source is temporarily disrupted (for example, electricity interruption due to a storm)	Reconnect device to power source and confirm the power status light on back of device is green (battery is charging). Press and hold the blue On/Off button to turn on the device. The display will show how many breaths are left in that treatment session. Press and immediately release (do not hold down) the blue button again to continue your treatment session.
	If device still does not function after taking corrective actions listed above, contact your specialty pharmacy provider for assistance.
Add Water screen appears	Water chamber is empty or distilled water level is too low.	Unplug device, if plugged in, and power off device. Remove dome assembly (making sure not to spill medicine) and place it aside, keeping it upright. Then empty water chamber. Refill water chamber with distilled water using water level cup (see page 32). Reassemble device. Power the device on and continue treatment.
	The distilled water is too pure.	Unplug device, if plugged in, and power off device. Remove dome assembly (making sure not to spill medicine) and place it aside, keeping it upright. Then empty water chamber. Add 1 teaspoon of tap water to the water level cup. Fill rest of cup with distilled water up to level between the 2 arrow markings on cup (see page 32). Pour cup's contents into water chamber. Reassemble device. Power the device on and continue treatment.
	Water level sensors have a thin layer of build-up	Unplug device, if plugged in, and power off device. Remove dome assembly (making sure not to spill medicine) and place it aside, keeping it upright. Then empty water chamber. Clean sensors and interior surfaces of water chamber with a clean cloth. Refill water chamber with distilled water using water level cup (see page 32). Reassemble device. Power the device on and continue treatment.
	If device still does not function after taking corrective actions listed above, contact your specialty pharmacy provider for assistance.
No "click" (or crunch) was heard when attaching the dome assembly	No medicine cup in the water chamber of the device	Unplug device, if plugged in, and power off device. Place an empty medicine cup into the water chamber of the device and fill it with 1 ampule of TYVASO. Reassemble device. Power the device on and continue treatment.
	Multiple medicine cups attached to the dome assembly	Unplug device, if plugged in, and power off device. Remove and dispose of all medicine cups in the device. Place a single, new medicine cup into device water chamber and fill with 1 ampule of TYVASO. Reassemble device. Power the device on and continue treatment.
	Dome assembly is not securely in place	Unplug device, if plugged in, and power off device. Align the raised circle on the side of the dome assembly with the raised circle on the side of the device.
		Push down and screw the dome assembly onto the device clockwise (right) until the filter shell port is tight and pointed to the back of the device and the raised circles line up again. You will hear clicks (or crunch sound) as the dome assembly presses down on the medicine cup. Reassemble device. Power the device on and continue treatment.
	If device still does not function after taking corrective actions listed above, contact your specialty pharmacy provider for assistance.
No medicine comes out of the device during a treatment session	No TYVASO® (treprostinil) Inhalation Solution in the medicine cup	Unplug device, if plugged in, and power off device. Fill medicine cup with 1 ampule of TYVASO. Reassemble device. Power the device on and continue treatment.
	Damaged medicine cup	Unplug device, if plugged in, and power off device. Remove and dispose of the medicine cup in the device. Empty the water chamber then refill it with 45 mL of distilled water (see page 32). Place a single, new medicine cup into water chamber and fill with 1 ampule of TYVASO. Reassemble device. Power the device on and continue treatment.
	Distilled water level in the water chamber is too high	Unplug device, if plugged in, and power off device. Remove dome assembly (making sure not to spill medicine) and place it aside, keeping it upright. Empty the water chamber then refill it with 45 mL of distilled water (see page 32). Reassemble device. Power the device on and continue treatment.
	Multiple medicine cups attached to the dome assembly	Unplug device, if plugged in, and power off device. Remove and dispose of all medicine cups in the device. Place a single, new medicine cup into water chamber and fill with 1 ampule of TYVASO. Reassemble device. Power the device on and continue treatment.
	If device still does not function after taking corrective actions listed above, contact your specialty pharmacy provider for assistance.
Difficult to breathe in medicine through the mouthpiece	Filter membrane is clogged	Unplug device, if plugged in, and power off device. Replace both filter membranes (see page 37). Reassemble device. Power the device on and continue treatment.
	If device still does not function after taking corrective actions listed above, contact your specialty pharmacy provider for assistance.

B: Specifications

Inhalation Device
Model	TD-300/A
Size	3.5" × 3.2" × 4.7" (90 × 82 × 120 mm)
Weight, inhalation device	365 g (12.8 oz)
Types of power supply	AC wall plug, 120 V, 60 Hz
Power input	14 V DC, 1.1 A maximum
Operating power consumption	18 Watt maximum
Ultrasonic frequency	2.4 MHz (nominal)
Nebulization rate	0.50 - 0.55 mg/min (0.9% Saline)
Medicine cup capacity	6 mL, nominal
Water chamber capacity	45 mL, nominal
Electric protection class	II, Type BF
Storage temperature/humidity	15 to 30ºC/20-80% relative humidity
Operating temperature/humidity	15 to 25ºC/40-75% relative humidity
A-weighted sound pressure level	75 dBA (1 m), maximum

Packaging Dimensions (Approximate Length × Width × Height)
Patient Starter Kit (PSK)	13.0" × 12.4" × 9.2"
Monthly Refill Kit (MRK)	11.8" × 8.2" × 3.0"
Institutional Starter Kit (ISK)	13.0" × 12.4" × 9.2"

TYVASO Mass and Particle Specifications for 9 breaths
Mass Median Aerodynamic Diameter (MMAD)n=108 data points from r=3 inhalation devices. Each data point was 9 breaths.	mean = 2.0 µm SD = 0.3
Total Emitted Dose per Breathn=216 data points from r=6 inhalation devices. Each data point was 1 breath.	mean = 6.0 µg SD = 0.4
Total Aerosol Mass	mean = 58 µg SD = 5.9
Total Respirable Dose	mean = 44.6 µg SD = 3.5
Respirable Fraction	mean = 73% SD = 5
Geometric Standard Deviation (GSD)	mean = 2.6 SD = 0.4

Accessories
Note: Part number subject to change.
TD-300N-US	AC wall plug
TD-132	Medicine cup, Quantity - 32
ON-109	Filter membranes
ON-120/C	Plugs
ON-101/C	Filter shell
TD-103/C	Dome assembly with baffle plate
ON-104/C	Inhalation piece
ON-105/C	Mouthpiece
TD-118	Water level cup
TD-158	Carrying case
TD-155	Distilled water carrier

C: Electromagnetic compatibility (EMC)

The TYVASO Inhalation System has been tested and found to comply with the electromagnetic compatibility (EMC) limits for medical devices according to IEC 60601-1-2: (2007). Compliance is intended to provide reasonable protection against harmful interference in a typical user environment. Table 1, Table 2 and Table 3 document the intended EMC use environment and established compliance levels for the TYVASO Inhalation System. To ensure the intended performance, use the system in the environments described in these tables. The TYVASO Inhalation System is intended for use in the electromagnetic environment specified in this section.

Table 1: Guidance and manufacturer's declaration - electromagnetic emissions

Guidance and manufacturer's declaration - electromagnetic emissions
The TYVASO Inhalation System is intended for use in the electromagnetic environment specified below. The customer or the user of the TYVASO Inhalation System should assure that it is used in such an environment.
Emissions test	Compliance	Electromagnetic environment - guidance
RF emissions CISPR 11	Group 1	The TYVASO Inhalation System uses RF energy only for its internal function. Therefore, its RF emissions are very low and are not likely to cause any interference in nearby electronic equipment.
RF emissions CISPR 11	Class B	The TYVASO Inhalation System is suitable for use in all establishments, including domestic establishments and those directly connected to the public low voltage power supply network that supplies buildings used for domestic purposes.
Harmonic emissions IEC 61000-3-2	Class A
Voltage fluctuations/flicker emissions IEC 61000-3-3	Complies

Table 2: Guidance and manufacturer's declaration – electromagnetic immunity

NOTE: U T is the a.c. mains voltage prior to application of the test level. NOTE 1: At 80 MHz and 800 MHz, the higher frequency range applies. NOTE 2: These guidelines may not apply in all situations. Electromagnetic propagation is affected by absorption and reflection from structures, objects and people.
Guidance and manufacturer's declaration – electromagnetic immunity
The TYVASO Inhalation System is intended for use in the electromagnetic environment specified below. The customer or the user of the TYVASO Inhalation System should assure that it is used in such an environment.
Immunity test	IEC 60601 Test level	Compliance level	Electromagnetic environment - guidance
Electrostatic discharge (ESD) IEC 61000-4-2	± 8 kV contact ± 15 kV air	± 8 kV contact ± 15 kV air	Floors should be wood, concrete or ceramic tile. If floors are covered with synthetic material, the relative humidity should be at least 30%.
Electrical fast transient/burst IEC 61000-4-4	± 2 kV for power supply lines ± 1 kV for input/output lines	± 2 kV for power supply lines ± 1 kV for input/output lines	Mains power quality should be that of a typical commercial or hospital environment.
Surge IEC 61000-4-5	± 1 kV line(s) to line(s) ± 2 kV line(s) to earth	± 1 kV line(s) to line(s) ± 2 kV line(s) to earth	Mains power quality should be that of a typical commercial or hospital environment.
Voltage dips, short interruptions and voltage variations on power supply input lines IEC 61000-4-11	0 % U T (100 % dip in U T) for 0,5 cycle 0 % U T (100 % dip in U T) for 1 cycle 70 % U T (30 % dip in U T) for 25/30 cycles 0 % U T (100 % dip in U T) for 250/300 cycle	0 % U T (100 % dip in U T) for 0,5 cycle 0 % U T (100 % dip in U T) for 1 cycle 70 % U T (30 % dip in U T) for 25/30 cycles 0 % U T (100 % dip in U T) for 250/300 cycle	Mains power quality should be that of a typical commercial or hospital environment. If the user of the TYVASO Inhalation System requires continued operation during power mains interruptions, it is recommended that the TYVASO Inhalation System be powered from an uninterruptible power supply or the internal battery.
Power frequency (50/60 Hz) magnetic field IEC 61000-4-8	30 A/m	30 A/m	Power frequency magnetic fields should be at levels characteristic of a typical location in a typical commercial or hospital environment.
Conducted RF IEC 61000-4-6 Radiated RF IEC 61000-4-3	3 Vrms 150 kHz to 80 MHz 10 V/m 80 MHz to 2.6 GHz	3 Vrms 150 kHz to 80 MHz 10 V/m 80 MHz to 2.6 GHz	Portable and mobile RF communications equipment should be used no closer to any part of TYVASO Inhalation System, including cables, than the recommended separation distance calculated from the equation applicable to the frequency of the transmitter. Recommended separation distance d = 1.2 √P d = 1.2 √P 80 MHz to 800 MHz d = 2.3 √P 800 MHz to 2.5 GHz where P is the maximum output power rating of the transmitter in watts (W) according to the transmitter manufacturer and d is the recommended separation distance in meters (m). Field strengths from fixed RF transmitters, as determined by an electromagnetic site surveyField strengths from fixed transmitters, such as base stations for radio (cellular/cordless) telephones and land mobile radios, amateur radio, AM and FM radio broadcast and TV broadcast cannot be predicted theoretically with accuracy. To assess the electromagnetic environment due to fixed RF transmitters, an electromagnetic site survey should be considered. If the measured field strength in the location in which the TYVASO Inhalation System is used exceeds the applicable RF compliance level above, the TYVASO Inhalation System should be observed to verify normal operation. If abnormal performance is observed, additional measures may be necessary, such as re-orienting or relocating the TYVASO Inhalation System., should be less than the compliance level in each frequency rangeOver the frequency range 150 kHz to 80 MHz, field strengths should be less than [V1] V/m.. Interference may occur in the vicinity of equipment marked with the following symbol:

Table 3: Manufacturer's Declaration – Recommended separation distances between portable and mobile communications equipment and the TYVASO Inhalation System

For transmitters rated at a maximum output power not listed above, the recommended separation distance d in meters (m) can be estimated using the equation applicable to the frequency of the transmitter, where P is the maximum output power rating of the transmitter in watts (W) according to the transmitter manufacturer. NOTE 1: At 80 MHz and 800 MHz, the separation distance for the higher frequency range applies. NOTE 2: These guidelines may not apply in all situations. Electromagnetic propagation is affected by absorption and reflection from structures, objects and people.
Recommended separation distances between portable and mobile RF communications equipment and the TYVASO Inhalation System
The TYVASO Inhalation System is intended for use in an electromagnetic environment in which radiated RF disturbances are controlled. The customer or the user of the TYVASO Inhalation System can help prevent electromagnetic interference by maintaining a minimum distance between portable and mobile RF communications equipment (transmitters) and the TYVASO Inhalation System as recommended below, according to the maximum output power of the communications equipment.
Rated maximum output power of transmitter W	Separation distance according to frequency of transmitter m
	150 kHz to 80 MHz d = 1.2 √P	80 MHz to 800 MHz d = 1.2 √P	800 MHz to 2.5 GHz d = 2.3 √P
0.01	0.12	0.12	0.23
0.1	0.38	0.38	0.73
1	1.2	1.2	2.3
10	3.8	3.8	7.3
100	12	12	23

D: Glossary

Accessories: Parts of the TYVASO Inhalation System. See page 29. Ampule: A sealed, lightweight clear plastic vial containing a 1-day supply of TYVASO^® (treprostinil) Inhalation Solution. Black ring: A round seal that fits on the bottom of the dome assembly. The seal helps ensure that TYVASO does not mix with the distilled water in the device water chamber. Display screen: A small area on the inhalation device that provides instructions and device information. Distilled water: Water that is highly purified so that it contains only essential elements. Dome assembly: The plastic accessory that contains the baffle plate and connects the mouthpiece, inhalation piece, and filter shells to the base of the inhalation device. Filter membrane: The white pad that goes into the filter shells. Filter shells: Plastic accessories that hold the filter membranes. Inhalation indicator lights: Two green lights on the top surface of the inhalation device that signals when you should inhale. Inhalation piece: The plastic accessory that connects the mouthpiece with the dome assembly. Inhalation device: The base of the TYVASO Inhalation System to which the accessories connect. The inhalation device contains the display screen and lights. Inhale: How you will breathe in TYVASO with the TYVASO Inhalation System. Medicine cup: The disposable plastic cone-shaped cup into which TYVASO is poured. The medicine cup fits inside the water chamber. Mouthpiece: The plastic part that you will breathe through (using your mouth) to inhale TYVASO. On/Off, Start/Pause (blue) button: A manually activated control on the front of the device that switches between fully on and fully off power states. Once the device power is on, the button begins or pauses treatment. Plugs: Plastic accessories that are inserted into the openings of the dome assembly between treatment sessions. Plugs help keep TYVASO from spilling if the inhalation device tips over. Power status light: LED on the back of the device that lights green when power is connected and battery is charging. Power port: Port on back of device for plugging into a power source using the AC wall plug. Prompts: The audio and visual signals that help guide you through the treatment sessions. Run / Program switch: A manually activated control on the side of the device that switches between the modes for delivering treatment (Run) and programming breaths (Program). Sensors: The silver objects on the inside wall of the water chamber. The sensors must be covered with distilled water for the TYVASO Inhalation System to function properly. Specialty pharmacy provider: A pharmacy that carries only specialized medicines and medical devices. Your specialty pharmacy provider is a good source of information about TYVASO and the TYVASO Inhalation System. Treatment session: 1 of 4 daily sessions during which you will take TYVASO with a specific number of inhalations. TYVASO: The prescription medicine that you will use with the TYVASO Inhalation System. Volume / Breaths toggle button: A manually activated control on the side of the device that increases or decreases audio volume (when in Run mode) and programmed breaths (when in Program mode). Water chamber: The white hollow portion in the center of the inhalation device into which distilled water and the medicine cup are placed.

E: Warranty information

Your TYVASO Inhalation System is granted a replacement or repair warranty good for 2 years from your date of receipt of the TYVASO Inhalation System or 5 years from the date of manufacture, whichever comes first. This warranty applies to the TYVASO Inhalation System device only. Accessory components are not covered under warranty.

Circumstances that may void your warranty include:
▶ Modification or disassembly of the TYVASO Inhalation System device by anyone other than a factory-authorized technician
▶ Failure to comply with this written Instructions for Use manual when operating the TYVASO Inhalation System
▶ Unapproved use of the TYVASO Inhalation System

For all inquiries relating to service or warranty for your TYVASO Inhalation System, contact your specialty pharmacy provider.

You should have the following information available:
▶ Device serial number (located on bottom of TYVASO Inhalation System)
▶ Date TYVASO Inhalation System was acquired
▶ Nature of the problem and any steps taken to fix it

TYVASO ^®
INHALATION SYSTEM TYVASO ^®
(treprostinil)
INHALATION
SOLUTION TYVASO Inhalation Solution is for prescription use only.

Emergency contact information
▶ Clinician:
▶ Nurse educator:
▶ Specialty pharmacist:
▶ United Therapeutics:

For further questions and information, or to report a problem with your device or an adverse event with your TYVASO Inhalation System, please call 1-844-UNITHER (1-844-864-8437). Distributed by:
United Therapeutics Corporation
Durham, North Carolina 27713 © 2025, United Therapeutics Corporation.
All rights reserved. 102131 TYVASO is a registered trademark of
United Therapeutics Corporation. This Instructions for Use has been
approved by the U.S. Food and Drug
Administration. Revised: October 2025 Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure

TYVASO®
(treprostinil)
INHALATION
SOLUTION Treprostinil 1.74 mg / 2.9 mL (0.6 mg/mL) Four 2.9 mL ampules For oral inhalation use only See package insert and
Instructions For Use manual
for dosage and administration Principal Display Panel - 4 Ampule Pouch Carton

TYVASO®
(treprostinil)
INHALATION
SOLUTION Treprostinil 1.74 mg / 2.9 mL (0.6 mg/mL) Seven foil pouches each containing four
2.9 mL ampules For oral inhalation use only See package insert and
Instructions For Use manual
for dosage and administration. PRINCIPAL DISPLAY PANEL - 28 Ampule Pouch Carton

TYVASO Inhalation System Patient Starter Kit TYVASO^®
(treprostinil)
INHALATION
SOLUTION Treprostinil 1.74 mg/2.9 mL (0.6 mg/mL) TYVASO is for oral inhalation use only and is intended for administration with the TYVASO Inhalation System.
See package insert and Instructions for Use manual for dosage and administration. 28 ampule carton of TYVASO
(seven foil pouches, each containing four 2.9 mL ampules)AC wall plugsTYVASO Inhalation DeviceWater level cupTYVASO Inhalation System Instructions for Use manualPlugs for storage between treatment sessionsTreatment TrackerCarrying caseSets of Dome assembly, Inhalation piece,
Mouthpiece, and 2 Filter shellsDistilled water carrierMedicine cupsFilter membranes

+

+

+

+

+

+

+

+

+

+

+

+

CONTENTS	QTY	CONTENTS	QTY
1
2
2
1
1
2
1
1
2
1
32
65

Each ampule of TYVASO contains: treprostinil 1.74 mg. Each ampule also contains 18.9 mg sodium chloride,
18.3 mg sodium citrate dihydrate, 0.6 mg sodium hydroxide, 11.7 mg 1N hydrochloric acid, and water for injection.
Hydrochloric acid and sodium hydroxide may have been added to adjust pH. + One new ampule should be used each day. Each ampule of TYVASO (once opened and transferred to the
medicine cup) should remain in the device for no more than 1 day. Any remaining TYVASO and the medicine
cup should be discarded at the end of each day. +Once a foil pouch is opened, use ampules within 7 days. +Store unused ampules of TYVASO in the foil pouch until use, protected from light. +Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Patient Starter Kit For Single Patient Use Only.
Keep out of the reach of children.
NDC 66302-206-01
Rx only Manufactured by United Therapeutics Corporation
Durham, NC 27713 United
Therapeutics
A PUBLIC BENEFIT CORPORATION 102129
Rev. 01/2026 MATERIAL:
102132 LOT:
2102958 EXP:
2028 – AUG Device SN#1:
25083422 Device SN#2:
25083257 PRINCIPAL DISPLAY PANEL - Patient Starter Kit

TYVASO Inhalation System
Refill Kit TYVASO^®
(treprostinil)
INHALATION
SOLUTION Treprostinil 1.74 mg/2.9 mL (0.6 mg/mL) TYVASO is for oral inhalation use only and is intended for administration with the TYVASO Inhalation System.
See package insert and Instructions for Use manual for dosage and administration. 28 ampule carton of TYVASO
(seven foil pouches, each containing four 2.9 mL ampules)Filter membranesSet of Dome assembly, Inhalation piece,
Mouthpiece, and 2 Filter shellsPlugs for storage between treatment sessionsMedicine cupsTreatment Tracker

+

+

+

+

+

+

CONTENTS	QTY	CONTENTS	QTY
1
65
1
2
32
1

Each ampule of TYVASO contains: treprostinil 1.74 mg. Each ampule also contains 18.9 mg sodium chloride,
18.3 mg sodium citrate dihydrate, 0.6 mg sodium hydroxide, 11.7 mg 1N hydrochloric acid, and water for injection.
Hydrochloric acid and sodium hydroxide may have been added to adjust pH. +One new ampule should be used each day. Each ampule of TYVASO (once opened and transferred to the medicine
cup) should remain in the device for no more than 1 day. Any remaining TYVASO and the medicine cup should be
discarded at the end of each day. +Once a foil pouch is opened, use ampules within 7 days. +Store unused ampules of TYVASO in the foil pouch until use, protected from light. +Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Keep out of the reach of children. NDC 66302-206-02
Rx only Manufactured by United Therapeutics Corporation
Durham, NC 27713 United
Therapeutics
A PUBLIC BENEFIT CORPORATION 102136
Rev. 01/2026 LOT XXXXXXX
EXP YYYY-MMM
GTIN XXXXXXXXXXXXXX
S/N XXXXXXXXXXXX PRINCIPAL DISPLAY PANEL - Refill Kit

TYVASO Inhalation System
Institutional Starter Kit TYVASO^®
(treprostinil)
INHALATION
SOLUTION Treprostinil 1.74 mg/2.9 mL (0.6 mg/mL) TYVASO is for oral inhalation use only and is intended for administration with the TYVASO Inhalation System.
See package insert and Instructions for Use manual for dosage and administration. 4 ampule carton of TYVASO
(one foil pouch containing four 2.9 mL ampules)AC wall plugsTYVASO Inhalation DeviceWater level cupTYVASO Inhalation System Instructions for Use manualPlugs for storage between treatment sessionsTreatment TrackerCarrying caseSets of Dome assembly, Inhalation piece,
Mouthpiece, and 2 Filter shellsDistilled water carrierMedicine cupsFilter membranes

+

+

+

+

+

+

+

+

+

+

+

+

CONTENTS	QTY	CONTENTS	QTY
1
2
2
1
1
2
1
1
2
1
32
65

Each ampule of TYVASO contains: treprostinil 1.74 mg. Each ampule also contains 18.9 mg sodium chloride,
18.3 mg sodium citrate dihydrate, 0.6 mg sodium hydroxide, 11.7 mg 1N hydrochloric acid, and water for injection.
Hydrochloric acid and sodium hydroxide may have been added to adjust pH. +One new ampule should be used each day. Each ampule of TYVASO (once opened and transferred to the
medicine cup) should remain in the device for no more than 1 day. Any remaining TYVASO and the medicine
cup should be discarded at the end of each day. +Once a foil pouch is opened, use ampules within 7 days. +Store unused ampules of TYVASO in the foil pouch until use, protected from light. +Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Institutional Starter Kit For Single Patient Use Only.
Keep out of the reach of children.
NDC 66302-206-04
Rx only Manufactured by United Therapeutics Corporation
Durham, NC 27713 United
Therapeutics
A PUBLIC BENEFIT CORPORATION 102130
Rev. 01/2026 MATERIAL:
102133 LOT:
2102764 EXP: 2027
– SEP Device SN#1:
25078743 Device SN#2:
25078749 PRINCIPAL DISPLAY PANEL - Institutional Starter Kit